The global sales of peri-implantitis treatment are estimated to be worth USD 2,689.1 million in 2024 and are anticipated to reach a value of USD 5,191.9 million by 2034. Sales are projected to rise at a CAGR of 6.8% over the forecast period between 2024 and 2034. The revenue generated by Peri-implantitis Treatment in 2023 was USD 2,517.9 million.
In various clinical settings, missing teeth have been replaced with dental implants, such replacement being established and popular option therapeutically. Dental implants have had significant problems in the past one such being peri-implantitis-a local infectious state that involve soft and hard tissues surrounding the implant. An inflammation around the implant can cause bone loss that supports it; this affects both the stability and longevity of dental implants in the patient's mouth.
As reported by National Center for Biotechnology Information, peri-implantitis is relatively common in the United States. In a cohort study with subjects participating for two years, it was found that the prevalence of peri-implantitis in patients was 34% and for implants was 21%. Such numbers can display how common this process can occur considering the all on the increased need for dental implants based on esthetic and functional reasons in dentistry.
Global Peri-implantitis Treatment Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 2,517.9 million |
| Estimated Size, 2024 | USD 2,689.1 million |
| Projected Size, 2034 | USD 5,191.9 million |
| Value-based CAGR (2024 to 2034) | 6.8% |
One of the most important factors fueling the growth of the periodontal diseases market is the adoption of dental implants. More patients are getting dental implants meaning that there are more people likely to develop peri-implantitis. At the same time, an increasing number of health care providers have realized the importance of timely identification and management of peri-implantitis thereby boosting the market further.
However, this market lacks much public awareness towards the treatment of peri-implantitis and its risks and symptoms are unknown to many patients. Furthermore, delayed diagnosis of patients who do finally ask for treatment can lead to a potential worse outcome.
Individuals who have had a history of exhibiting signs of periodontal disease are inherently at a higher risk of developing peri-implantitis, which supports the market further. This figures is reveled by CDC, that around 47.2% of adults in the United States aged 30 and up had a history of periodontal disease in 2019.
Prosthetic rehabilitation treatment options include dental implants, which have successfully restored function and aesthetics. A strong support for dental prostheses by dental implants which allows an improved and more natural chewing appearance, with patients indicating a high degree of satisfaction, and an increase in quality of life.
Emergent research has indicated dental implants to provide a prolonged area of successful serviceability, resulting in dental implants lasting several decades. In some cases, affected by patient compliance and maintenance following implants placement. Buyer's behaviors also refer to dental implants as a reliable and durable treatment option for replacing missing teeth and minimizing complications over time.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The table below compares the compound annual growth rate (CAGR) for the global Peri-implantitis Treatment market from 2023 to 2024 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics.
H1 covers January to June, while H2 spans July to December. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.8%, followed by a slightly lower growth rate of 7.4% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.8% (2023 to 2033) |
| H2 | 7.4% (2023 to 2033) |
| H1 | 6.8% (2024 to 2034) |
| H2 | 6.5% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 6.8% in the first half and projected to lower at 6.5% in the second half. In the first half (H1) the market witnessed a decrease of 100 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
Advancements in Early Detection and Treatment Drive Growth in Peri-Implantitis Market
A key force in developing the peri-implantitis field has been the growing body of evidence emphasizing the importance of early detection, managing risk factors, and the need for individualized treatment alternatives. In the past several years, we have witnessed remarkable improvements in identifying and treating peri-implantitis in implant dentistry.
These advances have initiated calls for early intervention, in addition to more personalized treatment protocols based on the extent and phenotype of the disease. Improved diagnostic criteria and classification systems, along with new treatment methodologies, offer renewed hope for the management and treatment of peri-implantitis.
Moving forward, research on advancements will ultimately progress the market forward as improved clinical outcomes and satisfied patients are achieved. Improved diagnostics and treatment regimens allow for better management of peri-implantitis and decrease its burden in implant therapy.
This enhanced management of peri-implantitis improves the long-term success of dental implants and will drive demand for peri-implantitis solutions. The continued development of advancing knowledge about peri-implantitis will ensure that patients receive better treatment and resultant mini-expansion of the peri-implantitis treatment market.
Emergence of Innovative Treatment Technologies Present New Opportunities for Peri-implantitis Treatment
Among the foremost opportunities in the treatment of peri-implantitis is the continued advent of new therapeutic technology. As a result of biotechnology and material science advancements, new instrumentation, diagnostics, and therapies are being developed to manage peri-implantitis more effectively (e.g., novel antimicrobials, current regeneration, and enhanced imaging technologies).
To illustrate, novel biomaterials and bioactive recovery of dental implants may shorten the risk of infection while improving healing or integration (chemical bonding) related to peri-implantitis.
These biomaterials and activators may also optimize implant connection with reparative tissues and enhance the efficacy of regenerative procedures. With advanced diagnostics, new precision periodontal measures may utilize high-resolution 3D scans, along with enhanced radiography that allows for more accurate detection of bone loss and a reasonable understanding of the rate of peri-implantitis progression.
The adoption of these upgraded technologies consistently indicates not only better management of peri-implantitis but also improved outcomes for patients. By investing in and applying these technologies, dental practitioners can offer a more comprehensive set of preventative and therapeutic options, generating increased demand for a more advanced peri-implantitis approach to treatment. This creates a great opportunity, likely resulting in significant market growth that promotes both the risk of advanced technology and improved patient care.
Increasing Use of Dental Implants and Aging Population in Developed Countries
The increasing utilization of dental implants for prosthetic rehabilitation is one of the significant factors that is anticipated to be a driver of growth for the global peri-implantitis market over the forecast period. Increased public awareness and concern about oral hygiene will lead to more dental visits, thus driving demand for the market for peri-implantitis treatment.
In addition, population growth with an expanding elderly population will accelerate growth in the need for peri-implantitis treatment for the forecast period. Technological leaps have helped create several dental techniques like dental grafting that will help to present new and exciting opportunities for market participants in the peri-implantitis market.
One of the observed leading causes of increased growth in the treatment of peri-implantitis is emerging tobacco use and smoking use, both of which are related to an increase in oral disorders. Furthermore, there will be an increase in opportunities to grow the market with an emerging interest in antiaging products and procedures for wrinkles, age spots, and other procedures by an aging population. Lastly, the interest in Microdermabrasion devices will likely increase and develop popularity among consumers of dental hygiene devices.
High Cost and Shortage of Skilled Specialists to Lower the Market Growth
The high costs associated with dental implants considerably impede the growth of the peri-implantitis treatment industry. The financial strain on the patient community can limit referral behavior and restrict access to necessary treatments.
Furthermore, the expense of peri-implantitis treatments can be prohibitively high for many patients, exacerbating the challenge of effective disease management. Additionally, a lack of adequately trained dental specialists to treat peri-implantitis compounds the issue, as insufficient numbers of specialists are available in many developing countries to diagnose and address the disease effectively.
Another challenge concerning diagnosis is there is often little to no diagnostic modalities for detecting bone loss associated with peri-implantitis until the radiograph shows a loss of approximately 30% of bone mass.
Understanding that a lack of knowledge around peri-implantitis and its treatment options for patients and dentists alike is another limitation, especially prevalent in developing areas. A lack of education about the treatment options for peri-implantitis leads to generally underdiagnosed and delayed treatment of many patients.
The identified barriers to diagnosis and treatment of peri-implantitis can be addressed through learning opportunities, direct training, and educational outreach programs, as well as reduced cost setups for training purposes and thereby contribute to improvement on a global scale and ultimately improved patient outcomes.
Principal Consultant
The global Peri-implantitis Treatment industry recorded a CAGR of 5.8% during the historical period between 2019 and 2023. The growth of Peri-implantitis Treatment diagnostics industry was positive as it reached a value of USD 5,191.9 million in 2034 from USD 2,689.1 million in 2024.
The market for peri-implantitis treatment has grown alongside advancements in dental implant technology. Initially, peri-implantitis treatment was restricted to primitive treatments such as mechanical debridement and antibiotic therapy. An increased awareness of peri-implantitis rapidly developed with increased dental implant placement in the community.
Treatment approaches were subsequently developed that are better targeted toward treating the disease. Over the past decade, heightened early diagnosis, and potential interventions for treatment of the disease. This has fueled by advances in diagnostic imaging and a greater understanding of the risk factors in development. New technologies have developed advanced biomaterials and regenerative treatments which increase the effectiveness of treatment.
The market for treating peri-implantitis is likely going to experience strong growth when factoring in recent trends. In the future, technology will significantly influence Class I diagnostic methods via diagnostic technology that is highly sensitive including high-resolution radiography, polymerase chain reaction, and sequencing methods among others. These methods would allow early intervention; diagnosis and precise medicines administration among others that are equally beneficial.
Tier 1 companies are the major companies as they hold a 29.5% share worldwide. These companies are developing advanced biomaterials, regenerative treatments, and improved diagnostic tools to enhance the effectiveness of peri-implantitis management. Prominent companies within tier 1 include Pfizer Inc., Straumann AG and Fotona Tier 2 companies are relatively smaller as compared with tier 1 players.
The tier 2 companies hold a share of 33.7% worldwide. Tier 2 companies are committing resources to R&D to stay at the forefront of technological advancements and innovation in the field. Key Companies under this category include Cadila Pharmaceuticals, Basic Pharma Life Sciences R N. Laboratories, and Triveni Chemicals.
Compared to Tiers 1 and 2, Tier 3 companies offer peri-implantitis treatment, but with smaller revenue spouts and less influence. These companies mostly operate in one or two countries and have limited customer base. Tier 3 companies, although, smaller but are essential for the market. The companies such as Prachi Pharmaceuticals, Healthy Life Pharma Private Limited and other falls under this category.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the peri-implantitis treatment market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided.
The United States is anticipated to remain at the forefront in North America, with a CAGR of 2.1% through 2034. In Asia Pacific, India is projected to witness the highest CAGR in the market of 7.7% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| India | 7.7% |
| China | 6.8% |
| South Korea | 5.4% |
| USA | 2.1% |
| Germany | 2.3% |
The USA dominates the global market with high share in 2023. The USA is expected to exhibit a CAGR of 2.1% throughout the forecast period (2024 to 2034).
Increasing incidence rates of peri-implantitis and escalating treatment costs and complexity are advancing prevention as a key focal point in the USA Given the irreversible aspect of peri-implantitis with limited efficacies in treatment and extreme costs, prevention plays an imperative role in attempting to prevent the disease.
The goal of prevention involves a multi-faceted approach, including improved oral hygiene, regular dental appointments, and prompt intervention to treat risk factors, such as poorly controlled periodontal disease and inadequate oral hygiene.
Educational strategies for patients and dental professionals focused on prevention may yield significant improvements in preventing peri-implantitis. For example, by improving education about implant care and proper maintenance, the rates of peri-implantitis can be substantially reduced.
The field is seeing better educational development and advances in preventative-based technologies used with implants, including antimicrobial coatings with implants and better diagnostic technologies.
This time on prevention not only aides in maintaining the rates of implants sustained, but it also represents a lower cost of unsuccessful treatments required for advanced peri-implant diseases. As such, there appears to be a trend towards prevention and managing peri-implantitis in the USA.
In 2023, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 2.3%.
Non-surgical debridement of the implant and surrounding tissues has been established as a commonly utilized intervention for peri-implant mucositis and peri-implantitis in Germany. Non-surgical debridement is a less invasive modality compared to surgical techniques and, therefore, is regarded favorably both by patients and clinicians. The results of non-surgical debridement include lower patient discomfort, shorter recovery times, and lower rates of procedural complications.
Non-surgical debridement is focused on cleaning, decontaminating, and implanting surface and tissues around the implants before the need for surgery, which provides benefits to the patient by minimizing patient trauma and recovery occurring more quickly.
Due to the positive outcomes and that it is patient-friendly, the non-surgical debridement being adopted contributes a lot to the growth of the peri-implantitis treatment market in Italy. The more patients and clinicians get to know about the benefits if this method, it becomes more and popular.
China occupies a leading value share in East Asia market in 2023 and is expected to grow with a CAGR of 6.8% during the forecasted period.
The rapid development emerging in China and its growing tourism economy have a strong effect on dental care provision including peri-implantitis treatment. The country is experiencing high growth rates so more private medical facilities are available to provide high-quality, along with low-cost dental care.
The partnership formed by Western companies and their Chinese dental implant manufacturing partners has been beneficial for advancing dental care in China. These partnerships are developing dental care in China to go along with the most shared Western therapies and technology.
Expatriates in major cities like Shanghai and Beijing can find clinics that offer Western-style dental care. However, for the general population finding high-quality dental care is lacking in major cities.
However, international partnerships and private medicalization, are expanding more and more to give one suspect, a better quality treatment matter peri-implantitis. Eventually, this will broaden the available peri-implantitis treatment options across china, which could be an efficient opportunity for the peri-implantitis treatment market growing in the region.
The section contains information about the leading segments in the industry. Based on method type, the surgical treatment of surgical treatment of peri-implantitis is expected to account 68.4% of the global share in 2024.
| Method Type | Surgical Treatment of Surgical Treatment |
|---|---|
| Value Share (2024) | 68.4% |
By method type, surgical treatment of peri-implantitis is expected to hold a share of 68.4% in 2024. Surgically treating peri-implantitis can produce great advantages over non-surgical options and will certainly be a viable treatment option in the markets.
Surgical treatments compared to non-surgical options can offer some financial way advantages. Surgical treatment can be an initial expense but once performed, it may serve peri-implantitis more effectively and may eliminate the need for costly routine and recurring treatment.
The surgical approach results in more effective management of peri-implantitis with high accuracy. Accuracy improves when the target tissue can be accessed directly, ensuring complete cleaning and decontamination of the implant surface. Therefore, surgical treatment is associated with an increased likelihood of treatment efficacy, with a lower frequency of infection occurrence after surgery, leading to better patient outcomes at long-term follow-up appointments.
| By End User | Hospitals |
|---|---|
| Value Share (2024) | 72.5% |
By end user, hospitals will account for 72.5% of the indication segment in 2024, and exhibit the highest CAGR in the forecast period.
Hospitals are leading the peri-implantitis treatment market significantly due to greater capabilities in technologies and capabilities to handle comprehensive care indefinitely. The hospitals will have sophisticated diagnostic and biomedical devices for treatment that will enhance the efficacy of treatment and accuracy in the management via the diagnosis of peri-implantitis.
These include imaging systems and surgical instruments that will enhance the efficacy and accuracy of management in peri-implantitis. Similarly, hospitals have systems capacity and resources to handle complicated illness processes and patients receiving approximately identical treatment. For example, at a hospital, there is the potential of transferring the patient to an inpatient room for significant treatment and hourly vital checks overnight versus a dental office where there is just a chair.
Therefore, the level of capability will drive the brand for patients who may require extensive, specialized treatment, which will be easier at the hospital. Overall, hospitals have advanced technologies but more importantly specialists that are advantageous to patients to manage peri-implantitis.
To remain competitive, key producers in the peripheral microcatheter market are focused on a number of strategic initiatives. The key players are making major investments in R&D to improve materials and designs aimed at better performance and safety of the catheters. Companies are forming alliances with each other and acquiring smaller companies for broadening their product portfolios and accessing newly surfaced technologies.
Recent Industry Developments in peri-implantitis treatment Market
In terms of method type, the industry is divided into surgical treatment of peri-implantitis (mechanical debridement, laser debridement, open flap debridement, open flap debridement with guided bone generation), non-surgical treatment of peri-implantitis (surface debridement, antibiotics (chlorhexidine digluconate), others.
In terms of end user, the industry is segregated into peri-implantitis treatment in hospitals and peri-implantitis treatment in dental clinics
Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East and Africa (MEA) have been covered in the report.
The global Peri-implantitis Treatment industry is projected to witness CAGR of 6.8% between 2024 and 2034.
The global Peri-implantitis Treatment industry stood at USD 2,517.9 million in 2023.
The global Peri-implantitis Treatment industry is anticipated to reach USD 5,191.9 million by 2034 end.
China is expected to show a CAGR of 6.8% in the assessment period.
The key players operating in the global Peri-implantitis Treatment industry include Pfizer Inc., Cadila Pharmaceuticals, R N. Laboratories, Triveni Chemicals, Basic Pharma Life Sciences, Prachi Pharmaceuticals, Healthy Life Pharma Private Limited, Straumann AG and Fotona.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. By Method 5.2. By End User 5.3. By Region 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Method 6.1. Surgical Treatment of Peri-Implantitis 6.1.1. Mechanical Debridement 6.1.2. Laser Debridement 6.1.3. Open Flap Debridement 6.1.4. Open Flap Debridement with Guided Bone Generation 6.2. Non-Surgical Treatment of Peri-Implantitis 6.2.1. Surface Debridement 6.2.2. Antibiotics (Chlorhexidine Digluconate) 6.2.3. Others 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User 7.1. Peri-Implantitis Treatment in Hospitals 7.2. Peri-Implantitis Treatment in Dental Clinics 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 8.1. North America 8.2. Latin America 8.3. East Asia 8.4. South Asia and Pacific 8.5. Western Europe 8.6. Eastern Europe 8.7. Middle East and Africa 9. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 10. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Middle East and Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Sales Forecast 2024 to 2034 by Method and End User for 30 Countries 17. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 18. Company Profile 18.1. Pfizer Inc. 18.2. Cadila Pharmaceuticals 18.3. R N. Laboratories 18.4. Triveni Chemicals 18.5. Basic Pharma Life Sciences 18.6. Prachi Pharmaceuticals 18.7. Healthy Life Pharma Private Limited 18.8. Straumann AG 18.9. Fotona
Explore Healthcare Insights
View Reports
Peri-implantitis Treatment Market
